Editas Medicine Statistics

Total Valuation

Editas Medicine has a market cap or net worth of $276.95 million. The enterprise value is $119.59 million.

Market Cap	276.95M
Enterprise Value	119.59M

Important Dates

The last earnings date was Tuesday, August 12, 2025, after market close.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Editas Medicine has 89.92 million shares outstanding. The number of shares has increased by 1.46% in one year.

Current Share Class	89.92M
Shares Outstanding	89.92M
Shares Change (YoY)	+1.46%
Shares Change (QoQ)	+1.63%
Owned by Insiders (%)	0.37%
Owned by Institutions (%)	49.66%
Float	83.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.58
Forward PS	n/a
PB Ratio	14.03
P/TBV Ratio	14.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	3.07
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.77, with a Debt / Equity ratio of 1.10.

Current Ratio	2.77
Quick Ratio	2.72
Debt / Equity	1.10
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-37.96

Financial Efficiency

Return on equity (ROE) is -188.58% and return on invested capital (ROIC) is -64.62%.

Return on Equity (ROE)	-188.58%
Return on Assets (ROA)	-33.76%
Return on Invested Capital (ROIC)	-64.62%
Return on Capital Employed (ROCE)	-111.17%
Revenue Per Employee	$158,134
Profits Per Employee	-$962,841
Employee Count	246
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.43% in the last 52 weeks. The beta is 2.20, so Editas Medicine's price volatility has been higher than the market average.

Beta (5Y)	2.20
52-Week Price Change	-21.43%
50-Day Moving Average	2.49
200-Day Moving Average	1.91
Relative Strength Index (RSI)	61.15
Average Volume (20 Days)	2,439,426

Short Selling Information

The latest short interest is 7.85 million, so 8.73% of the outstanding shares have been sold short.

Short Interest	7.85M
Short Previous Month	8.52M
Short % of Shares Out	8.73%
Short % of Float	9.42%
Short Ratio (days to cover)	2.64

Income Statement

In the last 12 months, Editas Medicine had revenue of $38.90 million and -$236.86 million in losses. Loss per share was -$2.85.

Revenue	38.90M
Gross Profit	-100.12M
Operating Income	-160.80M
Pretax Income	-193.45M
Net Income	-236.86M
EBITDA	-154.07M
EBIT	-160.80M
Loss Per Share	-$2.85

Full Income Statement

Balance Sheet

The company has $178.50 million in cash and $21.14 million in debt, giving a net cash position of $157.37 million or $1.75 per share.

Cash & Cash Equivalents	178.50M
Total Debt	21.14M
Net Cash	157.37M
Net Cash Per Share	$1.75
Equity (Book Value)	19.19M
Book Value Per Share	0.22
Working Capital	116.86M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$201.36 million and capital expenditures -$3.58 million, giving a free cash flow of -$204.94 million.

Operating Cash Flow	-201.36M
Capital Expenditures	-3.58M
Free Cash Flow	-204.94M
FCF Per Share	-$2.28

Full Cash Flow Statement

Margins

Gross Margin	-257.38%
Operating Margin	-413.35%
Pretax Margin	-608.88%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Editas Medicine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.46%
Shareholder Yield	-1.46%
Earnings Yield	-85.52%
FCF Yield	-74.00%

Analyst Forecast

The average price target for Editas Medicine is $5.44, which is 76.62% higher than the current price. The consensus rating is "Buy".

Price Target	$5.44
Price Target Difference	76.62%
Analyst Consensus	Buy
Analyst Count	11
Revenue Growth Forecast (5Y)	-12.72%
EPS Growth Forecast (5Y)	-17.95%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Editas Medicine has an Altman Z-Score of -11.64 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.64
Piotroski F-Score	1